Nutrigenomics: How Genes and Nutrition Interact
Using nutrition to benefit health through the care and feeding of genes, though still in its infancy, is an exciting field of study seeing exponential growth.
SCIG with Recombinant Human Hyaluronidase Is Safe and Preferred vs IVIG by Some Multifocal Motor Neuropathy Patients
A team of Dutch investigators enrolled 18 multifocal motor neuropathy (MMN) patients on intravenous immune globulin(IVIG) treatment in a prospective open-label study to evaluate the comparative safety of treatment with 10% human immune globulin whose subcutaneous administration is facilitated with recombinant human hyaluronidase (fSCIG) (HyQvia).
Excellent Response to Therapeutic Plasma Exchange in Myasthenia Gravis Patients with or Without Autoantibodies
A study out of the University of Texas Southwestern Medical Center found a 96 percent response rate to treatment with therapeutic plasma exchange (PLEX) in a series of 58 consecutive myasthenia gravis (MG) patients, with no significant difference in response between those with or without autoantibodies.
Novo Nordisk’s Esperoct Approved to Treat Individuals with Hemophilia A
FDA approved Esperoct (antihemophilic factor[recombinant], glycopegylatedexei), an extended half-life factor VIII molecule for replacement therapy in people with hemophilia A.
First Therapy Approved to Treat Rare Blood Clotting Disorder
FDA has approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive
therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura.
FDA Approves Hepatitis A and Measles Exposure Drug
FDA has approved Grifols’ GamaSTAN to treat people exposed to measles and the hepatitis A viruses.
Subcutaneous Lanadelumab Treatment Reduces Attack Rate in Patients with Hereditary Angioedema
Subcutaneous administration of lanadelumab, an investigational monoclonal antibody intended for the prevention of attacks in patients with type I or II hereditary angioedema (HAE), significantly reduced the mean number of attacks compared to placebo treatment.
Human Albumin as Drug Therapy for Decompensated Cirrhosis: A New Lifesaving Role for an Old Player?
A growing body of evidence suggests known pharmacologic properties of human albumin may contribute to reducing the risk of a range of cirrhosis complications, including bacterial sepsis, irreversible renal injury and death.
New Hemophilia A Treatment Approved by FDA
The U.S. Food and Drug Administration (FDA) has approved Bayer’s Jivi (BAY94-9027) as a preventive treatment for bleeding in hemophilia A.
Neonatal Fc Receptor Antagonist Efgartigimod Sustainably Reduces Circulating IgG Level in Humans
Investigators from the Belgian biotechnology company argenx and U.S. collaborators conducted a PhaseI clinical study to assess a novel modified antibody Fc fragment (efgartigimod) that reduces the circulating IgG level by blocking neonatal Fc receptor-mediated IgG recycling.